US ▾
BIOX
Earnings call · Jun 2026 (Q4 FY26)

Bioceres Crop Solutions Q4 FY26 earnings call BIOX

Sep 15, 2026 Source

Executive summary

Bioceres Crop Solutions Q4 FY26 — Cost Actions Drive Positive Adjusted EBITDA Amidst Litigation

Bioceres Crop Solutions faced a challenging FY26 marked by litigation and a seed business reconfiguration, leading to an 18% revenue decline. However, Q4 showed stabilization with broadly flat revenues and a return to positive adjusted EBITDA, driven by significant cost reductions. The company is now focused on portfolio rationalization, operational efficiencies, and addressing its capital structure, targeting improved gross margins and reduced SG&A in the coming fiscal years.

Highlights

5

  • Q4 FY26 revenues from continuing operations were broadly stable year-over-year at $55.9 million, slightly above the prior year's $55.4 million.

  • Q4 FY26 adjusted EBITDA improved significantly to positive $0.6 million, up from negative $9.6 million in the prior year.

  • SG&A expenses were reduced by 19% in Q4 FY26, more than offsetting the decline in reported gross profit.

  • Crop nutrition segment revenue increased by 36% year-over-year in Q4 FY26, driven by micro-granulated fertilizer performance.

  • Gross profit percentage expanded from FY25 to FY26 when adjusted for non-recurring inventory obsolescence.

Concerns

5

  • FY26 revenues from continuing operations declined by 18% to $238 million.

  • FY26 reported gross profit was down 21% to $82.9 million, with a gross margin of 34.8%.

  • Q4 FY26 gross profit was $12.7 million, down 6%, with a gross margin of 22.8%, impacted by $4 million of non-recurring inventory adjustments.

  • FY26 adjusted EBITDA declined by 12% to $25.5 million compared to $28.9 million in FY25.

  • Net financial debt stood at $213.6 million as of June 30, with $100 million of secured notes classified as short-term due to ongoing litigation.

Guidance & targets

CategoryTargetConfidence
Gross Margins
approximately 40%
high materiality
High
Total SG&A as a percent of revenues
23%
medium materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
Crop Nutrition
Strong performance of micro-granulated fertilizer, with both high revenues and improved margins in Q4. For the full year, revenues were broadly stable, but inoculant revenues were lower, and micronutrient fertilizer increased gross profit by approximately 20%.
Main driver: performance micro-granulated fertilizer
$20.3M36%—Gross profit increased 37%
Crop Protection
Q4 revenue declined overall, but the objective portfolio delivered higher gross profit and improved margins year-over-year. For the full year, margins were broadly stable despite lower revenues.
———Gross profit improved
Seeds and Integrated Products
Q4 revenues were lower, with remaining seeds weighing on reported results. However, seed treatment packs delivered higher sales and approximately 40% growth in gross profit. Full-year decline was associated with the seed business reconfiguration.
Seed treatment packs sales: higherSeed treatment packs gross profit growth: approximately 40%
———Gross profit increased 40%

Risks & headwinds

Ongoing litigation with creditors and noteholders' dispute Ongoing

$100M secured note classified as short-term; $18.6M outstanding balance at year-end not reflecting Pro-Farm foreclosure.

Mitigation:Company continues to dispute acceleration and foreclosure process; evaluating constructive alternatives where possible.

Revenue decline from continuing operations FY26

18% decline in FY26, totaling $238M.

Mitigation:Focusing business on core capabilities, reducing cost structure, strengthening operating discipline, portfolio rationalization, and go-to-market channel optimization.

Non-recurring inventory adjustments Q4 FY26

$4M impact on Q4 gross profit.

Mitigation:Result of a comprehensive review following portfolio transition; benefits of improved profitability are expected to be more fully reflected in future periods.

What to watch in Q1 FY27

Resolution of litigation process

Next quarter and beyond
Current Ongoing legal proceedings in New York
Target Progress towards resolution or constructive alternatives

Why it matters

The ongoing litigation impacts the company's capital structure and financial flexibility, with a significant secured note classified as short-term.

We continue to recognize the significance of the ongoing litigation process in New York, where we'll continue to pursue the appropriate legal course, as well as evaluate constructive alternatives, where possible.

2 min read 6 chapters

Detailed narrative

Impact of Litigation and Business Reconfiguration

Fiscal year 2026 was significantly impacted by ongoing litigation with creditors and a strategic reconfiguration of the seed business. This led to an 18% decline in revenues from continuing operations, totaling $238 million for the full year. The seed business reconfiguration accounted for approximately half of this decline, with the remaining impact primarily in crop protection and international operations. The company continues to dispute the acceleration of a $100 million secured note and the related foreclosure process.

Q4 Stabilization and Cost Actions

The fourth quarter showed encouraging signs of stabilization, with revenues from continuing operations broadly stable year-over-year at $55.9 million. This stability, combined with aggressive cost actions implemented throughout the year, resulted in a return to positive adjusted EBITDA of $0.6 million in Q4, a significant improvement from negative $9.6 million in the prior year. SG&A expenses were reduced by 19% in the quarter, demonstrating the effectiveness of the cost reset.

Underlying Gross Margin Improvement

While reported Q4 gross profit was down 6% to $12.7 million, this included a $4 million non-recurring inventory adjustment. Excluding this, the company noted improved profitability across several core product categories. Specifically, crop nutrition gross profit increased 37%, and seed treatment packs delivered approximately 40% growth in gross profit. When adjusted for non-recurring obsolescence, the gross profit percentage expanded from FY25 to FY26, indicating a stronger underlying portfolio.

Operating Expense Reset and Leaner Structure

The company achieved a substantial reset of its operating expense base, with over $20 million of improvement in operating expenses for the full year. This offset a significant portion of the $22 million decline in gross profit, limiting the adjusted EBITDA decline to only 12% for the full year, reaching $25.5 million. This demonstrates a significantly leaner operational structure as the company enters fiscal year 2027, with further SG&A reductions targeted for FY28.

Capital Structure and Liquidity Management

Managing liquidity and capital structure remains a key priority. As of June 30, total financial debt was $225.9 million, with net financial debt at $213.6 million. The company successfully reprofiled approximately $28 million of bank debt and completed a voluntary maturity extension for $46.5 million of local bond debt in Argentina. Despite these efforts, the ongoing legal dispute classifies a $100 million secured note as short-term, impacting the balance sheet presentation.

Strategic Roadmap and Future Focus

Following the seed business reconfiguration and an external strategic assessment, Bioceres has a clear roadmap for the next phase. This includes rationalizing its portfolio, optimizing go-to-market channels, revisiting commercial policies, and realigning R&D investments with financial objectives. The company aims to achieve approximately 40% gross margins for FY27 and beyond by focusing on high-quality core revenue streams and simplifying its product portfolio, alongside targeting 23% SG&A as a percentage of revenues by FY28.

AI-generated summary of the company's earnings call. Not investment advice.